Search

Wide Consensus Reached at Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine'

DUBLIN, March 25: Wide consensus emerged at the Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine’ on the need for radical change if Europe's approach to healthcare is to benefit from the potential of personalised medicine.

Read more

Master Class

Enhance your skills and expand your network with advanced online hematology training based on specially crafted clinical cases.

Read more

EHA mapping of adolescent and young adult (AYA) hematology patient care

EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.

Read more

EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies

In collaboration with the Armenian Hematology Association. Dates: October 20-21, 2017
Location: Yerevan, Armenia
Chairs: S Daghbashyan, JJ Kiladjian & P Fenaux
Language: English (with simultaneous translation to Russian)

Online registration is closed.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia

EHA in close collaboration with the Estonian Society of Haematology, the Lithuanian Society of Hematology and the Latvian Hematology Society are organizing the first EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia.

Read more

Turkey tutorial focused on lymphoma

The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more